Home>
US Stocks>
Protagonist Therapeutics

Protagonist Therapeutics share price today

(PTGX)

Protagonist Therapeutics share price is $39.49 & ₹3,367.31 as on 27 Dec 2024, 2.30 'hrs' IST

$39.49

▲

0.19

(0.48%)

Market is closed - opens 8 PM, 27 Dec 2024

View live Protagonist Therapeutics share price in Dollar and Rupees. Guide to invest in Protagonist Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Protagonist Therapeutics. Get details on the Indian mutual funds that are investing in Protagonist Therapeutics. Get Analyst recommendations and forecasts along with all the Protagonist Therapeutics's financials.

Protagonist Therapeutics share price movements

Today's Low: $38.85
Today's High: $39.61
$39.49
1.63%
Downside
Day's Volatility :1.93%
Upside
0.3%
52 Weeks Low: $21.43
52 Weeks High: $48.89
$39.49
45.73%
Downside
52 Weeks Volatility :56.17%
Upside
19.23%

Protagonist Therapeutics Returns

Period	Protagonist Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-11.8%	-9.0%	0.0%
6 Months	13.42%	-4.6%	0.0%
1 Year	69.91%	3.0%	0.0%
3 Years	15.55%	0.0%	-21.1%

Protagonist Therapeutics Key Statistics

in dollars & INR

Previous Close	$39.3
Open	$38.98
Today's High	$39.61
Today's Low	$38.845
Market Capitalization	$2.3B
Today's Volume	$248.7K
52 Week High	$48.89
52 Week Low	$21.43
Revenue TTM	$323.8M
EBITDA	$150.1M
Earnings Per Share (EPS)	$2.74
PE Ratio	14.34
Profit Margin	52.77%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	40.97%

How to invest in Protagonist Therapeutics from India?

It is very easy for Indian residents to invest directly in Protagonist Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Protagonist Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Protagonist Therapeutics or PTGX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Protagonist Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Protagonist Therapeutics shares which would translate to 0.022 fractional shares of Protagonist Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Protagonist Therapeutics, in just a few clicks!

Returns in Protagonist Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Protagonist Therapeutics investment value today

Current value as on today

₹1,73,056

Returns

₹73,056

(+73.06%)

Returns from Protagonist Therapeutics Stock

₹70,731 (+70.73%)

Dollar Returns

₹2,325 (+2.33%)

Indian investors sentiment towards Protagonist Therapeutics

167%

Period: Sep 27, 2024 to Dec 26, 2024. Change in 30 Days versus previous period

Search volume for Protagonist Therapeutics on INDmoney from India has grown in the last 30 days as on Dec 27, 2024. 167% more investors are searching Protagonist Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Protagonist Therapeutics

Farallon Capital Management, L.L.C.
9.83%
BlackRock Inc
9.66%
RTW INVESTMENTS, LLC
9.10%
Vanguard Group Inc
7.07%
State Street Corp
5.34%
Johnson & Johnson
4.11%

Analyst Recommendation on Protagonist Therapeutics

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Protagonist Therapeutics(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Protagonist Therapeutics

What analysts predicted

Upside of 45.61%

Current:

$39.49

Target:

$57.50

Insights on Protagonist Therapeutics

Price Movement
In the last 1 year, PTGX stock has moved up by 70.7%
PTGX vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 25.2% return, outperforming this stock by 10.5%

Protagonist Therapeutics Technicals Summary

Sell

Neutral

Buy

Protagonist Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Protagonist Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Protagonist Therapeutics Inc	-12.57%	13.42%	69.91%	15.55%	448.88%
Regeneron Pharmaceuticals, Inc.	-5.12%	-32.02%	-18.97%	11.91%	91.19%
Biontech Se	-3.72%	42.02%	7.95%	-52.72%	226.93%
Alnylam Pharmaceuticals, Inc.	-3.99%	0.1%	24.29%	44.19%	112.09%
Vertex Pharmaceuticals Incorporated	-12.61%	-12.92%	-0.27%	83.92%	86.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Protagonist Therapeutics Inc	14.34	14.34	0.0	2.53	0.41	0.2	NA	8.94
Regeneron Pharmaceuticals, Inc.	17.67	17.67	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Protagonist Therapeutics Inc	Buy	$2.3B	448.88%	14.34	52.77%
Regeneron Pharmaceuticals, Inc.	Buy	$78.5B	91.19%	17.67	33.61%
Biontech Se	Buy	$27.4B	226.93%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	112.09%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$105.1B	86.41%	32.84	-4.51%

About Protagonist Therapeutics

protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist

Organization	Protagonist Therapeutics
Employees	126
CEO	Dr. Dinesh V. Patel Ph.D.
Industry	Health Technology

Management People of Protagonist Therapeutics

Name	Title
Dr. Dinesh V. Patel Ph.D.	CEO, President, Secretary & Director
Mr. Asif Ali	Executive VP & Chief Financial Officer
Dr. Suneel K. Gupta Ph.D.	Chief Development Officer
Dr. Mark Smythe Ph.D.	Founder & VP Technology
Mr. Mohammad Masjedizadeh Ph.D.	Executive VP & Chief Technical Officer
Mr. Matthew M. Gosling J.D.	Executive VP & General Counsel
Ms. Carena Spivey	Head of HR & Senior VP of Human Resources
Dr. Ashok Bhandari Ph.D.	Executive VP & Chief Drug Discovery and Preclinical Development Officer
Mr. Carter J. King	Executive Vice President of Business Development
Ms. Abha Bommireddi	Executive Vice President of Portfolio & Program Management

Important FAQs about investing in Protagonist Therapeutics from India :

What is Protagonist Therapeutics share price today?

Protagonist Therapeutics share price today stands at $39.49, Open: $38.98 ; Previous Close: $39.30 ; High: $39.61 ; Low: $38.85 ; 52 Week High: $48.89 ; 52 Week Low: $21.43. The stock opens at $38.98, after a previous close of $39.30. The stock reached a daily high of $39.61 and a low of $38.85, with a 52-week high of $48.89 and a 52-week low of $21.43.

Can Indians buy Protagonist Therapeutics shares?

Yes, Indians can invest in the Protagonist Therapeutics (PTGX) from India.

With INDmoney, you can buy Protagonist Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Protagonist Therapeutics at zero transaction cost.

How can I buy Protagonist Therapeutics shares from India?

It is very easy to buy Protagonist Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Protagonist Therapeutics be purchased?

Yes, you can buy fractional shares of Protagonist Therapeutics with INDmoney app.

What are the documents required to start investing in Protagonist Therapeutics stocks?

To start investing in Protagonist Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.